Month: November 2020

99970-84-0,99970-84-0, [2,2′-Bipyridine]-4,4′-dicarbaldehyde is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(5) Preparation of compound (6); To a compound (5) (0.13 g, 0.7 mmol) and KtOBu (0.2 g, 1.8 mmol), THF 20 mL was added, and the compound (3) (0.75 g, 1.8 mmol) was dissolved in 20 mL of THF and slowly added dropwise, and then the reaction mixture was agitated at 70 C for 12 hours. After the reaction, the solvent was removed and an organic layer was extracted with MC and separated by recrystallization.

99970-84-0 [2,2′-Bipyridine]-4,4′-dicarbaldehyde 4171663, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; DONGJIN SEMICHEM CO., LTD.; WO2009/82163; (2009); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

54258-41-2, 1,10-Phenanthrolin-5-amine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

54258-41-2, 5-Amino-1,10-phenanthroline (471 mg, 2.42 mmol) and 2,6-pyridinedicarbaldehyde (135 mg, 1 mmol) were refluxed in EtOH (20 mL) containing a catalytic amount of acetic acid for 6 h, giving a suspension. The reaction mixture was filtered hot, and the solid was washed with EtOH to afford the desired product as a yellow solid. Yield: 451 mg (92.2%). 1H NMR (300 MHz, CDCl3): delta = 7.48 (s, 2H), 7.65 (dd, J = 8.1, 4.5 Hz, 2H), 7.72 (dd, J = 8.4, 4.5 Hz, 2H), 8.14 (t, J = 7.5 Hz, 1H), 8.27 (d, J = 8.4 Hz, 2H), 8.57 (d, J = 7.5 Hz, 2H), 8.82 (d, J = 8.4 Hz, 2H), 8.96 (s, 2H), 9.17 (d, J = 3.9 Hz, 2H), 9.27 (d, J = 4.2 Hz, 2H). ESI-MS: m/z 490.4 (M+H)+, 512.4 (M+Na)+. IR numax (KBr, cm-1): 3399s (br), 1626s, 1593s, 1562m, 1501m, 1486m, 1453w, 1421s, 1385m, 1337w, 1298w, 1265w, 1209w, 1142w, 1061m, 993w, 977w, 941w, 866m, 799m, 738s, 679w, 626m, 526w, 458w, 412w.

54258-41-2 1,10-Phenanthrolin-5-amine 606970, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Cheng, Feixiang; Ren, Mingli; He, Chixian; Yin, Hongju; Inorganica Chimica Acta; vol. 450; (2016); p. 170 – 175;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1119-97-7,MitMAB,as a common compound, the synthetic route is as follows.

General procedure: In a typical synthesis of DA-La(PW11)2, an aqueous solution of (2.0 g, 0.31 mmol) K-La(PW11)2 was dropped into a chloroform solution of (1.1 g, 3.75 mmol) DA-Br. A white precipitate formed after the addition of the whole K-La(PW11)2 aqueous solution and then the product was separated after a further 1 h of stirring. The product was washed twice with H2O and dried in air [9]. DDA-La(PW11)2, TDA-La(PW11)2, HDA-La(PW11)2 and ODA-La(PW11)2 were prepared with a similar procedure. In the 1H NMR spectra, the singlet peak at 2.5 ppm and 3.3 ppm is assigned to be DMSO-d6, and the water in DMSO-d6, respectively.

1119-97-7, As the paragraph descriping shows that 1119-97-7 is playing an increasingly important role.

Reference£º
Article; Zhao, Shen; Jia, Yueqing; Song, Yu-Fei; Applied Catalysis A: General; vol. 453; (2013); p. 188 – 194;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

1119-97-7, MitMAB is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

1119-97-7, General procedure: Aqueous NBTA3- solution is obtained by dissolving NBTA (33.4mg, 0.075mmol) into 150mL twice distilled water. Later, 3 eqvi. NaOH (9mg, 0.225mmol) is added to the aqueous solution. After sealing, the sample is stirred at 60C for 8h to ensure completely soluble. The concentration of NBTA3- solution is calculated as 5¡Á10-5M. Then, dissolving different quaternary ammonium salts into NBTA3- solution. After stirring for 30minat room temperature (25C), NBTA3-/ammonium salts solution become transparent, which then is subjected to further instruments analysis.

1119-97-7 MitMAB 14250, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Ma; Yang; Cao; Lei; Lei; Dyes and Pigments; vol. 140; (2017); p. 131 – 140;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

14162-95-9, 4-Bromo-2,2′-bipyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

14162-95-9, A 100 mL reactor was dried by keeping it in an ovenovernight; it was closed with a rubber stopper and waspurged with argon for 20 min. In the reactor, Pd(PPh3)2Cl2,(44 mg, 0.063 mmol, 0.03 eq.) CuI (42 mg, 0.209 mmol,0.10 eq.) were added and the reactor was purged with argon.Compound 6 (0.720 g, 2.089 mmol, 1 eq.) was added as asolution in benzene (10 mL). Further benzene (20 mL) wasadded along with TEA (1.328 g, 0.726 mL, 13.128 mmol, 6eq.) and the solution was left to stir at rt under argon. The 4-bromo-2,2?-bipyridine, (0.540 g, 2.298 mmol, 1.10 eq.) DBU(3.82 g, 3.75 mL, 25.07 mmol, 12 eq.) and water (16 mg, 16mul, 0.875 mmol, 0.40 eq.) were finally added and the solutionwas put in a pre-heated oil bath 60C, and left to react undervigorous stirring for 18 h. The reaction was stopped and thebenzene was removed under vacuum by distillation. Theresidue was extracted with diethyl ether (3 ¡Á 50 mL) andwater (50 mL). The organic layer was washed with 10% HCl(3 ¡Á 50 mL) and brine (1 ¡Á 50 mL) and the organic phasewas dried with Na2SO4, filtered and evaporated under vacuum.The crude was purified by chromatography on Biotageon silica (100 g) with dichloromethane-TEA (0.5%) and afterwith a gradient from dichloromethane to dichloromethane:ethyl acetate 8:2. A yellow solid was finally obtained: 849.6mg (95%). m.p.: 153-156C. 1H NMR (200 MHz, CDCl3) delta 8.70 (m,2H, H6pyr and H6?pyr), 8.56 (s, 1H, H3pyr), 8.41 (d, J = 8.0Hz, 1H, H3?pyr), 7.83 (td, J = 7.8, 1.8 Hz, 1H, H4pyr), 7.51(dd, J = 3.7, 1.2 Hz, 1H, H3 or H3?), 7.44 (dd, J = 5.0, 1.5Hz, 1H, H5 or H5?), 7.37 (dd, J = 5.1, 1.1 Hz, 1H, H5 orH5?), 7.34-7.29 overlapping (m, J = 7.5 4.8, 1.1, 1H, H5pyror H5?pyr), 7.26 (dd, J = 5.1, 1.1 Hz, 1H, H3 or H3?), 7.20(m (dd + s), 3.5, 1.2 Hz, 2H, H4? and H5pyr or H5?pyr), 7.09(dd, J = 5.1, 3.7 Hz, 1H, H4 or H4?).7.06 (dd, J = 5.1, 3.7Hz, 1H, H4 or H4?). 13C NMR (50 MHz, CDCl3) delta 156.43(C2q-pyr), 155.65 (C2?q-pyr), 149.38 (C6-pyr or C6?-pyr),149.27 (C6-pyr or C6?-pyr), 139.97 (C3?th), 137.09 (C5?th),136.08 (C4?pyr), 135.54 (C2th), 134.64 (C2?th), 132.41(C4pyr), 128.10 (C4?th), 127.51 (C5th or C5?th), 127.07(C5th or C5?th), 126.40 (C3?pyr), 126.11 (C3?th), 125.35(C4th or C4?th), 125.16 (C4th or C?th), 124.53 (C3pyr),124.14 (C2th), 122.96 (C3th), 121.32 (C5pyr or C5?pyr),116.87 (C5pyr or C5?pyr), 91.77 (C?C), 89.69 (C?C). MS(EI, m/z): 426.09. Elemental analysis: required forC24H14N2S3, C 67.57, H 3.31, N 6.57, S 22.55, found: C67.60, H 3.28, N 6.62, S 22.50.

The synthetic route of 14162-95-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Quagliotto, Pierluigi; Prosperini, Simona; Viscardi, Guido; Letters in Organic Chemistry; vol. 14; 7; (2017); p. 472 – 478;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4730-54-5,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4730-54-5,1,4,7-Triazacyclononane,as a common compound, the synthetic route is as follows.

General procedure: To a solution of 1,4,7-triazacyclononane (2 mmol) in distilled ethanol (50 mL) containing molecular sieve was added 1 equiv of aldehyde. The reaction mixture was stirred at room temperature. The solution was filtered and the filtrate was evaporated under reduced pressure to yield the aminal adduct.

The synthetic route of 4730-54-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Roger, Melissa; Patinec, Veronique; Bourgeois, Martine; Tripier, Raphael; Triki, Smail; Handel, Henri; Tetrahedron; vol. 68; 27-28; (2012); p. 5637 – 5643;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

485-71-2, Cinchonidine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,485-71-2

Example 11 (R)-1-(2-Hydroxyethyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylic acid cinchonidine salt To cinchonidine (46.98 g (159.6 mmol)), ethyl acetate (1400 mL) was added, and while heating and stirring the resulting mixture under reflux (about 78 C.), (RS)-1-(2-hydroxyethyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylic acid (50.00 g (159.6 mmol)) was added thereto. The resulting mixture was stirred for about 1 hour, and then gradually cooled to 20 to 30 C., and further stirred for about 1 hour at that temperature. The deposited crystal was filtered and washed with ethyl acetate (250 mL). The obtained wet crystal product was dried under reduced pressure at 40 C., whereby a crude product of the title compound (52.73 g) was obtained (yield: 54.4%). The diastereomeric excess of the obtained salt was 71.9% de. To the obtained crude product (50.00 g), ethanol (75 mL) and ethyl acetate (100 mL) were added, and the resulting mixture was heated and stirred under reflux (about 78 C.). After the mixture was stirred for about 1 hour, ethyl acetate (825 mL) was added thereto, and the resulting mixture was stirred under reflux again for about 0.5 hours. Thereafter, the mixture was cooled to 0 to 5 C. and stirred for about 1 hour at that temperature. The resulting crystal was filtered and washed with ethyl acetate (200 mL) cooled to 0 to 5 C. The obtained wet crystal product was dried under reduced pressure at 40 C., whereby the title compound was obtained (34.21 g, recovery rate: 68.4%, yield: 37.2%). The diastereomeric excess of the obtained salt was 98.7% de. 1H NMR (400 MHz, CDCl3) delta: 1.27-1.67 (m, 2H), 1.75-2.04 (m, 4H), 2.13-2.33 (m, 1H), 2.52-2.94 (m, 2H), 3.14-3.23 (m, 2H), 3.46-4.12 (m, 2H), 4.76-5.10 (m, 2H), 5.58-5.90 (m, 2H), 6.10-6.95 (m, 2H), 7.00-8.25 (m, 7H), 8.55-9.01 (m, 1H). MS (ESI): 313, 294

As the paragraph descriping shows that 485-71-2 is playing an increasingly important role.

Reference£º
Patent; Daiichi Sankyo Company, Limited; Watanabe, Masashi; Okachi, Takahiro; Kawahara, Michiaki; Nagasawa, Hiroshi; Sato, Noritada; Takita, Takashi; Hasegawa, Gen; (23 pag.)US2016/96803; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

68737-65-5, (1R,2R)-N,N’-Dimethyl-1,2-cyclohexanediamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 56 Preparation of N-(4-methylphenyl)benzamide using 4-chlorotoluene and N,N’-dimethyl-trans-1,2-cyclohexanediamine at 110 C. An oven-dried resealable Schlenk tube was charged with CuI (20 mg, 0.105 mmol, 5.1 mol %), benzamide (250 mg, 2.06 mmol), K2CO3 (600 mg, 4.34 mmol), evacuated and backfilled with argon. N,N’-Dimethyl-trans-1,2-cyclohexanediamine (35 muL, 0.222 mmol, 11 mol %) and 4-chlorotoluene (1.0 mL, 8.44 mmol) were added under argon. The Schlenk tube was sealed and the reaction mixture was stirred magnetically at 110 C. for 23 h. The resulting dark blue-green suspension was cooled to room temperature and filtered through a 0.5*1 cm pad of silica gel eluding with 10 mL of ethyl acetate. The light brown filtrate was concentrated and the residue was purified by flash chromatography on silica gel (2*20 cm; hexane-ethyl acetate 2:1; 15 mL fractions). Fractions 4-10 were concentrated, the solid residue was suspended in 10 mL of hexane and filtered to provide 392 mg (90% yield) of the product as fine white needles.

68737-65-5, 68737-65-5 (1R,2R)-N,N’-Dimethyl-1,2-cyclohexanediamine 2733821, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Buchwald, Stephen L.; Klapars, Artis; Antilla, Jon C.; Job, Gabriel E.; Wolter, Martina; Kwong, Fuk Y.; Nordmann, Gero; Hennessy, Edward J.; US2003/65187; (2003); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,62937-45-5

C) (2R)-1-((1-(4-(4-methyl-1H-pyrazol-1-yl)pyridin-3-yl)piperidin-4-yl)carbonyl)pyrrolidine-2-carbonitrile (crude crystals) To a suspension of 1-(4-(4-methyl-1H-pyrazol-1-yl)pyridin-3-yl)piperidine-4-carboxylic acid (80 g) and acetonitrile (0.32 L) were added DIPEA (0.21 L), (R)-prolinamide (40 g) and 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide (1.7M ethyl acetate solution, 0.28 L) at 0C. The mixture was stirred at room temperature for 1 hr, to the mixture was added 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide (1.7M ethyl acetate solution, 0.35 L), and the mixture was stirred overnight at 70C. To the mixture was added saturated aqueous sodium hydrogen carbonate solution (1600 mL) at 0C, and the mixture was extracted with a mixed solvent of ethyl acetate and THF. The organic layer was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solution was purified by silica gel column chromatography (ethyl acetate). The solvent was evaporated under reduced pressure, to the residue was added diisopropyl ether, and the mixture was stirred overnight at room temperature. The solid was collected by filtration, and washed with diisopropyl ether to give the title compound (93 g). 1H NMR (300 MHz, DMSO-d6) 5 1.57-1.82 (4H, m), 1.89-2.30 (7H, m), 2.53-2.83 (3H, m), 2.86-3.06 (2H, m), 3.41-3.58 (1H, m), 3.62-3.75 (1H, m), 4.72 (1H, dd, J = 7.4, 4.0 Hz), 7.53 (1H, d, J = 5.3 Hz), 7.63 (1H, s), 8.31 (1H, d, J = 5.3 Hz), 8.41 (1H, s), 8.43 (1H, s).

62937-45-5 D-Prolinamide 447554, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Takeda Pharmaceutical Company Limited; KOIKE, Tatsuki; KAJITA, Yuichi; YOSHIKAWA, Masato; IKEDA, Shuhei; KIMURA, Eiji; HASUI, Tomoaki; NISHI, Toshiya; FUKUDA, Hiromi; EP2933247; (2015); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33454-82-9,Lithium trifluoromethanesulfonate,as a common compound, the synthetic route is as follows.

General procedure: To the solution of 2-Cl (186 mg, 0.25 mmol) dissolvedin5.0 mL of methanol/CH2Cl2 (1/9), a 5% aqueous solution of sodiumtetrafluoroborate (1.5 g, 0.41 mmol) was added. The solution was stirredat room temperature for 1 h. Reaction was monitored by Alumina(Al2O3) TLC plate in MeOH/CH2Cl2 (5/95); an Rf ~ 0.9 of product washigher than Rf ~ 0.5 of 2-Cl. The organic layer was passed through ashort Al2O3 flash column. The crude product was collected after solventswere removed. The product isolated as fine off white powder was obtainedafter recrystallization from isopropanol/ethyl acetate. Yield 70%;, 33454-82-9

33454-82-9 Lithium trifluoromethanesulfonate 3664839, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Wang, Ren-Tzong; Jane Tsai, Suh-Jen; Lee, Gene-Hsiang; Lai, Chung K.; Dyes and Pigments; vol. 173; (2020);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI